Abstract
To achieve malaria elimination, new tools are required to explicitly target Plasmodium vivax. Recently, a novel panel of P. vivax proteins were identified and validated as serological markers for detecting recent exposure to P. vivax within the last 9 months. In order to improve the sensitivity and specificity of these markers, IgM in addition to IgG antibody responses were assessed to a down-selected panel of 20 P. vivax proteins. IgM was tested using archival plasma samples from observational cohort studies conducted in malaria-endemic regions of Thailand and Brazil. IgM responses to these proteins generally had poorer classification performance than IgG.
Competing Interest Statement
RJL, MW, TT and IM are inventors on patent PCT/US17/67926 on a system, method, apparatus and diagnostic test for Plasmodium vivax. No other authors declare a conflict of interest.
Funding Statement
This work was supported by the National Health and Medical Research Council Australia (#1092789, #1134989 and #1043345 to IM and #1143187 to W-HT), the National Institute of Allergy and Infectious Diseases (NIH grant 5R01 AI 104822 to JS) and the Global Health Innovative Technology Fund (T2015-142 to IM). The Brazilian team was partly funded by Fundacao de Amparo a Pesquisa do Estado do Amazonas-FAPEAM (PAPAC 005/2019 and Pro-Estado). ML and WM are research fellows from CNPq. Additional funding directly supporting field studies was from the TransEPI consortium (supported by the Bill and Melinda Gates Foundation). We also acknowledge support from the National Research Council of Thailand. This work was made possible through Victorian State Government Operational Infrastructure Support and Australian Government NHMRC IRIISS. The Walter and Eliza Hall Institute of Medical Research, through the Page Betheras Award to RJL, also provided salary support. RJL is currently supported by an NHMRC Early Career Investigator Fellowship (1173210). W.H.T. is a Howard Hughes Medical Institute-Wellcome Trust International Research Scholar (208693/Z/17/Z).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All individuals provided informed consent or assent, and the studies were approved locally by the Ethics Committee of the Faculty of Tropical Medicine, Mahidol University, Thailand (MUTM 2013-027-01), and the Brazilian National Committee of Ethics (CONEP) (349.211/2013). The Human Research Ethics Committee at WEHI approved usage of all samples at WEHI, and collection of the malaria-naive control samples (#14/02).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
(1) RJL, MW, TT and IM are inventors on patent PCT/US17/67926 on a system, method, apparatus and diagnostic test for Plasmodium vivax. No other authors declare a conflict of interest.
(2) This work was supported by the National Health and Medical Research Council Australia (#1092789, #1134989 and #1043345 to IM and #1143187 to W-HT), the National Institute of Allergy and Infectious Diseases (NIH grant 5R01 AI 104822 to JS) and the Global Health Innovative Technology Fund (T2015-142 to IM). The Brazilian team was partly funded by Fundaçâo de Amparo à Pesquisa do Estado do Amazonas-FAPEAM (PAPAC 005/2019 and Pro-Estado). ML and WM are research fellows from CNPq. Additional funding directly supporting field studies was from the TransEPI consortium (supported by the Bill and Melinda Gates Foundation). We also acknowledge support from the National Research Council of Thailand. This work was made possible through Victorian State Government Operational Infrastructure Support and Australian Government NHMRC IRIISS.
(3) Part of this work was presented by RJL at the 47th Annual Scientific Meeting of the Australasian Society for Immunology, December 2018, Perth, Australia.
(4) Correspondence and requests for reprints should be addressed to Professor Ivo Mueller, The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville 3052, Victoria, Australia, mueller{at}wehi.edu.au, +61 3 9345 2936.
Data Availability
Data are available within the manuscript and supplementary files.
